ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
1.320
-0.020 (-1.49%)
Jun 9, 2026, 4:00 PM EDT - Market closed
ABVC BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.14 | 0.68 | 0.25 | 0.06 | 0.09 | 5.83 |
Short-Term Investments | 0.06 | 0.06 | 0.06 | 0.08 | 0.08 | 0.11 |
Cash & Short-Term Investments | 0.2 | 0.75 | 0.31 | 0.14 | 0.16 | 5.94 |
Cash Growth | -6.79% | 138.20% | 124.51% | -13.41% | -97.29% | 38.93% |
Accounts Receivable | - | - | - | 0.01 | 0.86 | 0.43 |
Other Receivables | 0.2 | 0.76 | 1.16 | 0.75 | 0.51 | - |
Total Trade Receivables | 0.2 | 0.76 | 1.16 | 0.76 | 1.37 | 0.43 |
Inventory | - | - | - | - | - | 0.03 |
Other Current Assets | 0.25 | 0.99 | 0.71 | 0.76 | 1.46 | 1.27 |
Total Current Assets | 0.65 | 2.5 | 2.18 | 1.66 | 2.99 | 7.65 |
Net Property, Plant & Equipment | 14.65 | 14.75 | 1.15 | 1.38 | 1.74 | 2 |
Long-Term Investments | 1.85 | 1.88 | 2.26 | 2.53 | 0.84 | 0.93 |
Other Long-Term Assets | 2.59 | 1.93 | 1.95 | 2.22 | 4.02 | 3.11 |
Total Assets | 19.73 | 21.06 | 7.54 | 7.78 | 9.58 | 13.7 |
Accrued Expenses | 4.15 | 4.16 | 3.51 | 3.55 | 2.91 | 1.3 |
Short-Term Debt | 0.09 | 0.76 | 0.84 | 0.9 | 1.89 | 1.64 |
Current Portion of Long-Term Debt | 0.8 | 0.8 | 0.95 | 0.89 | - | - |
Current Portion of Leases | 0.33 | 0.32 | 0.4 | 0.4 | 0.37 | 0.35 |
Unearned Revenue | 0.01 | 0.01 | 0.08 | 0.08 | 0.01 | 0.01 |
Other Current Liabilities | 0.01 | 0.12 | 0.77 | 0.29 | 0.36 | 0.39 |
Total Current Liabilities | 5.39 | 6.16 | 6.56 | 6.1 | 5.54 | 3.69 |
Long-Term Leases | 1.51 | 1.6 | 0.24 | 0.41 | 0.79 | 1.12 |
Other Long-Term Liabilities | - | - | 0.02 | 0.02 | 0.01 | 0.01 |
Total Long-Term Liabilities | 1.51 | 1.6 | 0.26 | 0.43 | 0.8 | 1.14 |
Total Liabilities | 6.9 | 7.76 | 6.82 | 6.53 | 6.34 | 4.83 |
Common Stock | 0.03 | 0.03 | 0.01 | 0.01 | 0 | 0.03 |
Treasury Stock | -8.91 | -8.91 | -8.91 | -8.9 | -9.1 | -9.1 |
Additional Paid-in Capital | 97.58 | 96.37 | 78.63 | 73.98 | 66.58 | 55.86 |
Accumulated Other Comprehensive Income | 0.5 | 0.49 | 0.45 | 0.52 | 0.52 | 0.54 |
Retained Earnings | -78.42 | -76.86 | -68.95 | -64.05 | -54.9 | -38.48 |
Total Common Shareholders' Equity | 10.77 | 11.11 | 1.23 | 1.55 | 3.1 | 8.84 |
Minority Interest | 2.06 | 2.19 | -0.5 | -0.3 | 0.14 | 0.03 |
Shareholders' Equity | 12.83 | 13.3 | 0.72 | 1.25 | 3.24 | 8.87 |
Total Liabilities & Equity | 19.73 | 21.06 | 7.54 | 7.78 | 9.58 | 13.7 |
Total Debt | 2.73 | 3.47 | 2.43 | 2.6 | 3.05 | 3.11 |
Net Cash (Debt) | -2.53 | -2.73 | -2.12 | -2.46 | -2.89 | 2.82 |
Net Cash Per Share | -0.11 | -0.14 | -0.18 | -0.57 | -0.91 | 0.89 |
Book Value | 10.77 | 11.11 | 1.23 | 1.55 | 3.1 | 8.84 |
Book Value Per Share | 0.47 | 0.55 | 0.11 | 0.36 | 0.98 | 2.79 |
Tangible Book Value | 10.77 | 11.11 | 1.23 | 1.55 | 3.1 | 8.84 |
Tangible Book Value Per Share | 0.47 | 0.55 | 0.11 | 0.36 | 0.98 | 2.79 |